MedTrace Logo

A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab

NCT02515734 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2015-08-05

No results posted yet for this study

Summary

This study is to verify the advantage of FOLFOXIRI plus cetuximab over FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors.

Conditions

Interventions

DRUG

fluorouracil

DRUG

Leucovorin

DRUG

irinotecan

DRUG

oxaliplatin

BIOLOGICAL

bevacizumab

BIOLOGICAL

cetuximab

Sponsors & Collaborators

  • Japan Clinical Cancer Research Organization

    lead OTHER

Principal Investigators

  • Toshifusa Nakajima, MD · Japan Clinical Cancer Research Organization

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2017-12-31
Completion
2020-06-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02515734 on ClinicalTrials.gov